Download PDFPDF
Digitalis: a dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Digitalis in atrial fibrillation: not the best friend nor the worst foe.
    • Luca Testa, research/interventional fellow
    • Other Contributors:
      • Ravinay Bhindi and Adrian P Banning

    Dear Editor,

    We have carefully read the article by Gjesdal et al [1] showing the result of an exploratory analysis pooling data from the SPORTIF III and V trials [2,3]. By means of a Cox proportional hazard analysis the authors concluded that the use of digitalis may increase mortality.
    Although we acknowledge the merit of this manuscript, in our opinion some points deserve further elucidation....

    Show More
    Conflict of Interest:
    None declared.